ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Here's Why We're Not At All Concerned With ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
Form 144 | ARS Pharmaceuticals(SPRY.US) Officer Proposes to Sell 4.2 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Oct 15, $ARS Pharmaceuticals(SPRY.US)$ Officer Tanimoto Sarina intends to sell 300K shares of its common stock on Oct 15, with a total market value of approximately $4.2
Express News | ARS Pharmaceuticals Inc - as Partial Consideration for Deal, Co Obligated to Pay Nuova Upfront Payment of Three Mln Euros
Express News | ARS Pharmaceuticals- Unit Entered Supply Agreement With Nuova Ompi S.r.l.
Jasper Gains 11% on Data for Briquilimab in Urticaria
Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's Is How to Trade
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
Cantor Fitzgerald Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $30
ARS Pharmaceuticals (SPRY) Initiated With a Buy at Cantor Fitzgerald
Express News | ARS Pharmaceuticals Inc - Eligible Patients to Pay $25 for Two Neffy Devices
Express News | ARS Pharmaceuticals Announces U.S. Availability of Neffy® (Epinephrine Nasal Spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
ARS Pharmaceuticals Announces U.S. Availability of Neffy (Epinephrine Nasal Spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
ARS Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Express News | ARS Pharmaceuticals Inc : Leerink Partners Raises Target Price to $25 From $21
Institutional Investors Control 33% of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) and Were Rewarded Last Week After Stock Increased 14%
Ars Pharmaceuticals Insider Sold Shares Worth $1,149,775, According to a Recent SEC Filing
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
Form 144 | ARS Pharmaceuticals(SPRY.US) Officer Proposes to Sell 3.41 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 10, $ARS Pharmaceuticals(SPRY.US)$ Officer Lowenthal Richard E intends to sell 300K shares of its common stock on Sep 10, with a total market value of approximately $3.41
ARS Pharmaceuticals Submits SNDA to FDA for Neffy 1 Mg Dose for Pediatric Patients With Type I Allergic Reactions Who Weigh 15 to 30 Kg (33-66 Lbs.)